Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**(R)-9-palmitic acid hydroxystearic acid** is the R-enantiomer of 9-palmitic acid hydroxy stearic acid (9-PAHSA), a fatty acid ester of a hydroxy fatty acid (FAHFA) formed by esterification of palmitic acid with 9-hydroxystearic acid.[1][3][8] FAHFAs, including 9-PAHSA, are endogenous lipids found in mammals that exhibit antidiabetic and anti-inflammatory activities, acting as signaling lipids that improve glucose homeostasis and insulin sensitivity and reduce inflammatory responses.[1][3][5][8] The R stereoisomer is the predominant endogenous configuration in adipose tissue and is produced and degraded via stereospecific biosynthetic and hydrolytic enzymes, including adipose triglyceride lipase as a biosynthetic enzyme and carboxyl ester lipase with preference for the S isomer.[1] (R)-9-PAHSA is primarily used as a research chemical and molecular tool in lipid biology, metabolism, and inflammation studies, rather than as a therapeutic drug product.[1][2][3][5][7][8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (R)-9-palmitic acid hydroxystearic acid.